Avion Pharmaceuticals LLC

MYRTLE BEACH, S.C., Oct. 3, 2024 /PRNewswire/ -- Rock Steady Boxing is a health and wellness program designed for people with Parkinson's disease, a neurological condition that affects balance, strength, walking, and especially confidence. It's based on the foundation of a boxing-based fitness curriculum. From October 3rd to the 5th, the Coach Con event will bring together a diverse audience of more than 250 Rock Steady Boxing coaches including fitness professionals, clinicians, caregivers, and more. The purpose of this conference is to educate and inspire Rock Steady Boxing coaches and facilitate networking. One of the highlights at Coach Con will be Jimmy Choi. Mr. Choi is not only a Parkinson's disease patient but a 6-season competitor on American Ninja Warrior. At the age of 27, Jimmy Choi was diagnosed with young onset Parkinson's disease. Upon receiving the diagnosis, Jimmy went into denial for the next 7-8 years. Finally, in 2010, Jimmy acted and vowed to take back control of what Parkinson's disease had robbed from him physically, mentally, and emotionally. Since then, Jimmy has participated in multiple clinical trials to further research on better treatments and hopefully a cure for Parkinson's. Physical therapy led him to running and other activities that help both his physical and mental Parkinson's disease symptoms. Part of Jimmy's regimen includes taking Dhivy to help manage his Parkinson's disease. Dhivy is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease. It is the first and only functionally scored carbidopa/levodopa product to facilitate precise dose adjustment. "The ability to adjust the dosing precisely to help the patient manage their Parkinson's symptoms is important," states Harold "Art" Deas, Chief Executive Officer of Alora Pharmaceuticals. "The journey for each Parkinson's patient is unique and thus offering a scored CD/LD option helps support an individualized approach to pro-actively managing this disease," added Deas. At Coach Con, Jimmy will be meeting with coaches living with Parkinson's disease and will share and talk about ideas in exercise, nutrition, medicine and sustainable lifestyle changes that can help Rock Steady Boxers better prepare for their fight with Parkinson's disease. Jimmy stated, "My mission is to inspire and support others facing Parkinson's Disease and not let this disease define you or stop anyone from enjoying life. I try to find ways to defy the odds presented and help others know that when one road is blocked, change course. You will find a way." For more information about DHIVY, please visit dhivy.com. For full Prescribing Information, please visit About Alora Pharmaceuticals, LLC Alora Pharmaceuticals, LLC and its family of companies are focused on improving the quality of patient lives. Every day, healthcare providers, caregivers and patients rely upon Alora to deliver a comprehensive portfolio of branded and generic medicines that address important medical needs in women's health, endocrinology, neurology, dermatology and pediatrics among others. For more information, visit alorapharma.com. About Avion Pharmaceuticals, LLC Avion Pharmaceuticals, LLC, is a specialty pharmaceutical company formed to develop, acquire and market a portfolio of innovative pharmaceutical products in the Women's Health, Neurology and other therapeutic categories aligned with our mission to improve the quality of patient lives. Avion Pharmaceuticals focuses on identifying opportunities to develop, acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals, please contact the company at 888-612-8466. For more information, visit . SOURCE Alora Pharmaceuticals , LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ALPHARETTA, Ga., Oct. 1, 2024 /PRNewswire/ -- This ADHD Awareness Month, we stand with the ADHD community. Alora Pharmaceuticals, LLC, the largest U.S. manufacturer of methylphenidate medications,1 recognizes that ADHD impacts various aspects of daily life, from school to work to personal time. This month, let's all commit to increasing awareness and understanding of ADHD while fostering a more supportive environment. ADHD is among the most prevalent neurodevelopmental disorders in children and can be a lifelong disorder, with symptoms emerging in childhood and persisting into adulthood. Recognizing the signs of ADHD is an important step in obtaining a diagnosis.2 According to the Centers for Disease Control and Prevention (CDC), approximately 10.2% of children in the U.S., ages 3 to 17, have been diagnosed with ADHD.3 According to the National Institutes of Health (NIH), the percentage of adults with ADHD is estimated to be around 4-5%.4 These statistics indicate that millions of children and adults in the U.S. are living with this condition. Medication, along with behavioral therapy, is often used in ADHD treatment.2 Stimulants, like RELEXXII ®, are fast-acting and among the most well-known and frequently utilized medications for ADHD. The CDC states that 70-80% of children with ADHD experience a reduction in symptoms when using stimulant medications.5 "Raising awareness about ADHD is vital in breaking down barriers and fostering understanding. Accurate diagnosis and effective management are crucial for improving patient outcomes and quality of life. At Alora Pharmaceuticals, we strive to provide the resources and support needed to empower individuals with ADHD to reach their full potential," stated Shannon Faught, CCO of Alora Pharmaceuticals. For more information on RELEXXII® please visit relexxii.com. For Important Safety Information visit relexxii.com/isi. For full Prescribing Information, including BOXED WARNING, visit relexxii.com/pi. For U.S. residents only. About Alora Pharmaceuticals, LLC. Alora Pharmaceuticals, LLC is the parent company of six specialty pharmaceutical and pharmaceutical manufacturing companies. Headquartered in Alpharetta, GA, Alora is the parent company of the following organizations that comprise the Alora Family of Companies: Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, and Vertical Pharmaceuticals. For media inquiries or for more information about Alora's efforts to address the nationwide ADHD treatment supply shortage, please contact Alora Pharmaceuticals, LLC: 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005; 1-678-325-5189. Relexxii® is a registered trademark of Vertical Pharmaceuticals, LLC. References: 1. Data on file, Osmotica Pharmaceuticals. 2. 3. 4. 5. SOURCE Alora Pharmaceuticals , LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ALPHARETTA, Ga., Dec. 19, 2023 /PRNewswire/ -- Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii® (methylphenidate hydrochloride extended-release tablets). Relexxii is a once-daily central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and in pediatric patients 6 years of age and older.1 With the introduction of Relexxii, patients and health care professionals will have an additional branded ADHD treatment option from which to choose. Continue Reading Once-daily Relexxii is now widely available in flexible dosing options that support a more tailored treatment approach throughout the ADHD treatment journey: 18-mg, 27-mg, 36-mg, 45-mg, 54-mg, 63-mg, and 72-mg. This line of once-daily strengths has been specifically designed to support targeted titration to help achieve the lowest effective dose and to help mitigate the need for multiple daily pills. Once-daily Relexxii strengths are offered in 9-mg increments, yielding two "in-between" doses of 45-mg and 63-mg. Available in flexible dosing options that support a more tailored treatment throughout the ADHD treatment journey. Post this Relexxii once-daily dosing is made possible by Alora Pharmaceutical's Osmodex® Drug Delivery Technology, which allows the medication to be released at a controlled rate throughout the day. With the immediate-release drug layer dissolving within one hour of administration, patients get the medicine they need quickly — and for up to 24 hours — with each daily dose. In a study of 60 healthy volunteers, once-daily dosing of Relexxii 72-mg demonstrated bioequivalence to twice daily dosing of Concerta® (methylphenidate HCI) 36-mg tablets.2 "Alora Pharmaceuticals recognizes the importance of reliability when it comes to ADHD medications. Our mission of manufacturing supply to address the nationwide shortage is unwavering. With Relexxii, we can offer the consistency of a branded treatment for individuals affected by ADHD. Alora Pharmaceuticals remains committed to ensuring that patients have access to affordable medications that they need", stated Harold (Art) Deas, CEO of Alora Pharmaceuticals, LLC. To learn more about Relexxii or to find patient support resources, please visit . For Full Prescribing Information, including BOXED WARNING, please visit . About Alora Pharmaceuticals, LLC Alora Pharmaceuticals, LLC is the parent company of six specialty pharmaceutical and pharmaceutical manufacturing companies. Headquartered in Alpharetta, GA, Alora is the parent company of the following organizations that comprise the Alora Family of Companies: Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, and Vertical Pharmaceuticals. For media inquiries or for more information about Alora's efforts to address the nationwide ADHD treatment supply shortage, please contact Alora Pharmaceuticals, LLC: 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005; 1-678-325-5189. Relexxii® is a registered trademark of Vertical Pharmaceuticals, LLC. Osmodex® is a registered trademark of Acella Holdings, LLC. Concerta® is a registered trademark of ALZA Corporation. References: 1. Relexxii (methylphenidate hydrochloride extended-release tablets) package insert. Vertical Pharmaceuticals, LLC; 2023. 2. Data on file, Osmotica Pharmaceuticals US LLC. SOURCE Alora Pharmaceuticals , LLC